The NSABP B-41 trial is a Randomized Neoadjuvant Trial for HER2-positive operable breast cancer treated with neoadjuvant trastuzumab and chemotherapy (AC + T), with or without lapatinib [19]. This evidence concerns the gene ERBB2 and breast carcinoma.